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Accumulation of α-synuclein is observed in neurodegenerative diseases like Parkinson’s disease and Multiple System Atrophy.
In previous studies with transgenic C57BL/6 mice overexpressing α-synuclein carrying the mutations A53T and A30P found
in Parkinson’s disease or with a parkin-null background, we reported severe mitochondrial impairments in neurons and to a
larger extent in glial cells of the mesencephalon. Neuron death was not observed in the brain. Here we show that the mice show
severe motor impairments in behavioral tests. In addition, these mice exhibit astrocytic cell death in the spinal cord, accompanied
by extensive gliosis and microglial activation. This is shown by cell death staining and immunohistochemistry. Ultrastructural
analyses revealed severe mitochondrial impairments not only in astrocytes, but also in oligodendrocytes and, to a small extent, in
neurons. Thus, the transgenic mice show a profound pathology in glial cells of the spinal cord.
1.Introduction
Parkinson’s disease (PD) is a chronic neurodegenerative dis-
ease associated with severe motor impairments, substantial
morbidity, and increased mortality. The neuropathology of
PD is characterized by an excessive loss of dopaminergic
neurons in the substantia nigra, but other brain regions may
also be aﬀected. Most cases of PD are sporadic, with late
onset. However, 5–10% of PD cases are familial and can
be attributed to a mutation in genes like α-synuclein (α-
syn) and parkin [1]. α-syn is a synaptic molecule and it is
assumed that it is involved in membrane vesicle traﬃcking
and cytoskeletal dynamics [2]. Furthermore, aggregations of
α-syn are speciﬁc for α-synuncleinopathies like PD, Lewy
body disease, or Multiple System Atrophy (MSA) [3, 4]. It
seems to be that α-syn is degraded by Parkin, an E3 ubiquitin
ligase [5].
Several transgenic mouse models carrying α-syn and
parkin mutations have been used to elucidate the molecular
mechanisms of PD pathogenesis [6]. In previous studies,
we generated mice carrying a deletion in the parkin gene
and/or overexpressing the mutated human α-syn transgene
[7, 8]. These mice exhibit ultrastructural mitochondrial
alterations in neurons and, interestingly, to a larger extent
in glial cells of the mesencephalon, but they do not display
severe histopathological hallmarks such as cell death in the
substantia nigra. These data indicate that glial cells are active
contributors to the initiation or progression of PD [9, 10].
This is supported by cell culture data suggesting abnormal
functions of glial cells from mice carrying PD-inducing gene
mutations [11, 12]. Furthermore, glial cells have been shown
to express proteins like superoxide dismutase 1, huntingtin,
or ataxin which are linked to neurodegenerative diseases.
Recent studies suggest an important role for glial cells also
in other neurodegenerative diseases. For example, astrocytes
play a central role in the degeneration of spinal motor
neurons in amyotrophic lateral sclerosis [13] and oligoden-
drocytes are active contributors to neuronal degeneration in
MSA [14, 15].
Several clinical studies reported the appearance of
nondopaminergic symptoms like impairments in anxiety
behavior in early PD stages [16]. Recent literature suggests
that pathologic manifestations are ﬁrst detected in the spinal
cord and then progressing from caudal to rostral until2 Parkinson’s Disease
they reach the mesencephalon. This model, described by
Braak and coworkers [17], provides an explanation for the
appearance of nondopaminergic symptoms which precede
cell death in the substantia nigra. Autonomic dysfunctions
like depression, sleep disturbances, or anxiety behavior are
controlled by the lower brainstem and spinal ganglia [18].
Based on these reports, we now investigated whether a
caudal to rostral progression could also be observed in our
transgenic mice, since parkin and α-syn are expressed in
the spinal cord [19]. We found cell death, mitochondrial
alterations, and severe inﬂammatory reactions in glial cells
of the spinal cords of the mutated mice. In addition,
when looking at the motor abilities of the mice, we found
severe motor impairments which seem to be related to the
pathological changes in the spinal cord.
In summary, our transgenic mice carrying PD-inducing
gene mutations exhibit more severe pathological impair-
ments in glial cells of the spinal cord than in the mesen-
cephalon, similar to the situation in early PD described by
Braak and coworkers [17].
2. Methods
2.1. Mouse Strains. Two transgenic mouse lines were ana-
l y z e d :ah o m o z y g o u sα-syn line (C57BL/6J background)
overexpressing doubly mutated (A30P, A53T) human (hm2)
α-syn driven by the chicken β-actin (BAsyn) promoter as
describedpreviously[7],hereweusedtheBAsynline1.5and
a double-mutant mouse line carrying additionally a deletion
of exon3 in the parkin gene (BAsyn/PaKO; F10 generation,
99% C57BL/6J, and 1% 129SvJ). Control mice were age-
matched nontransgenic littermates (LMs).
Housing and breeding of animals were performed in
accordance with the German guidelines of the animal care
and use committee. All eﬀorts were made to minimize the
number of animals used and their suﬀering.
2.2. Tissue Preparation. Mice were anesthetized by an over-
dose of ketamine (100mg/kg) and rompun (5mg/kg) and
perfusedtranscardiallywithphosphate-buﬀeredsaline(PBS)
followed by 4% paraformaldehyde (PFA) in 0.1M phosphate
buﬀer (PB) for immunohistochemistry or 2% PFA plus 2.5%
glutaraldehyde (GA) in PB for electron microscopy. Cervical
parts of the spinal cord were immediately removed and
postﬁxed.
2.3. Immunohistochemistry and Cell Death Staining. Cervi-
cal parts of the spinal cord were embedded in paraﬃn.
For sequential double-labeling spinal cords were cut into
3μm-thick sections, for analyses of α-syn aggregations,
for cell death staining as well as for the investigations of
inﬂammatory processes spinal cords were cut into 18μm-
thick sections. The sections were deparaﬃnized and antigen
retrieval (5–10min cooking in 0.01M citrate buﬀer, pH
6.0) was performed (except for glial ﬁbrillary acidic protein
(GFAP) and myelin basic protein (MBP)). After preincuba-
tion (3% normal serum), sections were treated with mouse
antihumanα-syn(anti-syn211;1:700,Invitrogen),astrocyte
marker rabbit anticow GFAP (anti-GFAP; 1:1000; Acris),
oligodendrocyte marker goat antihuman MBP (anti-MBP;
1:1000; Santa Cruz), microglia marker goat antihuman
ionized calcium-binding adaptor molecule 1 (anti-Iba1;
1:250; Abcam), neuronal marker mouse antimouse neu-
ronalnuclei (anti-NeuN; 1:700; Chemicon), goatantimouse
cathepsin X (anti-CATX; 1:200; R&D Systems), and goat
antirat cathepsin S (anti-CATS; 1:200; Santa Cruz). Sections
were stained with the corresponding biotinylated secondary
antibody (1:300, Axxora), ABC reagent (1:100; Axxora),
and silver-gold intensiﬁcation.
FluoroJade and silver-staining were used to detect degen-
erating cells. Deparaﬃnized and rehydrated sections were
incubated in 0.06% potassium permanganate solution for
15min, rinsed with distilled water, and then incubated in a
solution of 0.01% FluoroJade (Histo-Chem) in 0.1% acetic
acid for 30min. Silver staining was performed according to
the protocol of Gallyas et al. [20].
2.4. Transmission Electron Microscopy. Postﬁxed (2h, 4◦C)
parts of the cervical spinal cord were cut with a vibratome
(100μm thick), anterior horn samples microdissected and
placed in 2% OsO4 for 1h, dehydrated with graded
concentrations of ethanol and Epon-propylene oxide, and
ﬂat embedded in Epon. Representative ultrathin sections
were collected on Formvar-coated grids and contrasted with
uranyl acetate and lead citrate.
Ultrathin sections were visualized using a Phillips EM-
410. Morphology and number of mitochondria were eval-
uated in digitized electron microscopic images of 8m-
old animals. In total, 24 somata per cell type (neurons,
astrocytes, and oligodendrocytes) taken from two vibratome
sections of each animal were independently analyzed by
two examiners blind with respect to the genotypes of the
mice. Ultrathin sections were selected at random from the
middleofthevibratomesectionstoavoidpotentialstructural
irregularities possibly occurring on the surface.
Data are presented as a mean ± standard deviation
(SD) of the means of the analyzed animals per genotype.
Statistical analyses of ultrastructural changes compared to
corresponding age-matched LMs were carried out using the
Mann-Whitney Rank Sum Test (U-test, two tailed, alpha
level 0.05).
2.5. Elevated Plus Test. Mice were placed on a cross-shaped
elevated maze with two open arms and two closed arms
which stands one meter above the ﬂoor. A video camera
recorded for 5min the horizontal path length, time in closed
arms, and duration and number of stops.
2.6. Footprints. To obtain the footprints, the hind paws of
the mice were dipped in a dye and the mice were placed
in a 100cm long and 4.5cm wide gangway. The ﬂoor was
lined with white paper and the footprints were analyzed with
aF o o t p r i n ts o f t w a r e .D a t aa r ep r e s e n t e da sm e a n± SD of
the means of the analyzed animals per genotype. Statistical
analyses were performed by using the Mann-Whitney Rank
Sum Test (U-test, two tailed, alpha level 0.05).Parkinson’s Disease 3
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Figure 1: Light microscopic phenotyping of cells expressing the transgene in BAsyn/PaKO mouse brains. Photomicrographs of serial, 3μm-
thick sections of the spinal cord from BAsyn/PaKO mice ((a)–(h)). The syn211-immunostaining (b) colocalized with the marker GFAP (a),
indicating the transgene expression in astrocytes. In the parts of the spinal cord where many Iba1-positive cells (c) are stained, it seems
that only one cell could be also positive for syn211 (d), indicating that it is not clear if the hm α-syn is expressed in microglia. For MBP-
immunopositive oligodendrocytes (e) and NeuN-immunopositive (g) neurons no match with syn211-immunostaining could be detected
((f), (h)). Scale bars: (a)–(d): 30μm; (e)–(h) 50μm.
3. Results
3.1. Cellular Distribution of the hm α-Syn in the Spinal Cord
of BAsyn and BAsyn/PaKO. We investigated and compared
the distribution of the human α-syn in the transgenic α-
synmouselines.Sequentialimmunoperoxidaselabelingwith
α-syn- and cell type-speciﬁc antibodies was performed.
Examples are shown for 8-month (m) old BAsyn/PaKO in
Figures 1(a)–1(h). BAsyn/PaKO expressed the transgene in
the spinal cord almost exclusively in astrocytes (Figures 1(a)
and 1(b)). In Figure 2(k), the α-syn distribution is shown for
a whole cross section of the spinal cord from BAsyn/PaKO,
indicating that the transgene is mostly expressed in white
matter. In this area we also found many GFAP-positive cells
(Figure 2(l)). It is not clear if the transgene is expressed in
microglia. The parts of the spinal cord with a large amount
of microglia showed nearly no α-syn expression (Figures
1(c) and 1(d)). However, it cannot be excluded that the
transgene is expressed in few isolated microglia. Neither for
immunopositive oligodendrocytes nor for stained neurons
an expression of the transgene could be detected (Figures
1(e)–1(h)).WefoundthesamecellulardistributioninBAsyn
mice (data not shown).
3.2. Severe α-Syn Aggregations, Inﬂammatory Reactions, and
Cell Death in the Spinal Cord of α-Syn Transgenics. We
analyzedthecervicalspinalcordof3-and8-moldBAsynand4 Parkinson’s Disease
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Figure 2: Immunohistochemical analyzes and cell death staining of the cervical spinal cord. Schematic illustration of the transversal spinal
cord (a). Cell death staining by FluoroJade and Gallyas are shown in (b) and (c) for BAsyn/PaKO. An example showed a cell positive for
GallyasandGFAPinadjacentslices((c),(d)).Immunopositivestructuresofthecervicalspinalcordforhmα-syn(withorwithoutproteinase
K), GFAP, Iba1, CATX, and CATS are shown for LM in (e)–(j) and for BAsyn/PaKO in (k)–(p). (q)–(v) are higher magniﬁcations of (k)–(p).
Scale bars: (e)–(p): 200μm; (q) and (r): 10μm, (s)–(v): 100μm, and details of (s)–(v): 10μm.Parkinson’s Disease 5
BAsyn/PaKO mice and their corresponding LM as illustrated
in Figure 2. We examined the expression of the hm α-syn
without (Figures 2(s), 2(k), and 2(q)) and with (Figures 2(f),
2(l), and 2(r)) pretreatment of the slices with proteinase K.
After pretreatment of the slices with proteinase K hm, α-
syn aggregations in the anterior horn (AH), zona intermedia
(ZI), lateral funiculus (LF), and in the anterior funiculus
(AF) of the spinal cord were visible in 8m-old BAsyn/PaKO
(Figures 2(l) and 2(r)). In contrast, no aggregations were
observed in LM (Figure 2(f)).
Next, we investigated the expression of GFAP and Iba1
and found an increased number of GFAP-positive cells
(Figures 2(m) and 2(s)) as well as a stronger expression of
Iba1 (Figures 2(n) and 2(t)) in the AH, ZI, LF, and in the AF
of the spinal cord of 8m-old BAsyn/PaKO compared to LM
(Figures 2(g) and 2(h)), indicating the occurrence of severe
gliosis.
This glial cell activation in the old BAsyn/PaKO was
accompanied by a higher expression of the lysosomal cystein
proteases CATX (Figures 2(o) and 2(u)) and CATS (Figures
2(p) and 2(v)). Expression of these markers is an early
indicator of inﬂammatory reactions. The two proteins were
visible in the same regions where gliosis was observed,
diﬀerent from the LM (Figures 2(i) and 2(j)).
In addition to the severe α-syn aggregations, gliosis and
inﬂammation, FluoroJade (Figure 2(b)) and Gallyas silver
staining (Figure 2(c)) indicated the occurrence of cell death
in the LF and AF of the cervical spinal cord of 8m-old
BAsyn/PaKO.Analysesofadjacentslicesshowedthatthecells
positive for Gallyas cell death staining were also stained by
astrocytes markers (Figures 2(c), 2(d)). No cell death could
be detected in motor neurons located next to the astrocytes.
The same analyzes were performed with the monomu-
tant line BAsyn and in two out of four animals we also found
α-syn aggregations, gliosis, inﬂammatory reactions as well
as cell death. However, two other animals did not display
these pathological changes (data not shown). Furthermore,
3m-old mice were investigated and neither young BAsyn nor
BAsyn/PaKO displayed these alterations (data not shown).
3.3.UltrastructuralImpairmentsofMitochondriaintheSpinal
Cord of the Double Mutants. The mitochondrial ultrastruc-
ture of neurons, astrocytes, and oligodendrocytes in the cer-
vical spinal cord was examined by electron microscopy. Glial
cells were counted if they contained a nucleus surrounded
by cytoplasm and were classiﬁed according to their typical
ultrastructuralfeatures[21,22].Brieﬂy,astrocyteswereiden-
tiﬁed by their electron-lucent cytoplasm and the appearance
of their nuclei (thin rim of heterochromatin adjacent to
nuclear membrane). Oligodendrocytes show electron-dense
cytoplasms and their nuclei are rich in clumped heterochro-
matin close to the border of the nucleus. Mitochondria
were classiﬁed as structurally damaged when one or more
of the following alterations were observed: distorted or
disrupted cristae, detachment of or protrusions from the
outer membrane, electron-lucent domains, or inclusions in
the matrix. At the age of 8m BAsyn/PaKO showed only
a slight mitochondrial damage in neurons (Figures 3(d)
and 3(g)), whereas LM exhibited nearly no impairments
(Figures 3(a) and 3(g)). In contrast, both astrocytes (Figures
3(e) and 3(g)) and oligodendrocytes (Figures 3(e) and 3(g))
of BAsyn/PaKO displayed a statistically signiﬁcant increase
in mitochondrial damage compared to the corresponding
cells in LM (Figures 3(b), 3(c),a n d3(g)). Oligodendrocytes
exhibited the highest number of altered mitochondria.
3.4. Behavioral Deﬁcits in Mono- and Double-Mutant Mice.
The gait of the 8m-old transgenic mice was investigated
by analyzing their footprints. The following parameters
were measured: stride length, stride width, foot length, area
touched, angle, and spread of toes 1–5 and 2–4 (Figure 4(a)).
Examinations revealed a decreased stride length for both
mono- and double-mutants (Figures 4(b)–4(c)).
The Elevated Plus Test measures the anxiety as well as
the willingness of mice to explore a new environment. Four
diﬀerent parameters were analyzed: distance, time in closed
arms, number of stops, and the duration of stops. Both 8m-
old BAsyn and BAsyn/PaKO walked shorter distances made
fewer stops and longer breaks than LM. The transgenic mice
spent by trend more time in the closed arms, however, this
diﬀerence is very low (Figures 5(a)–5(h)).
4. Discussion
While the pathological hallmark of PD is the degeneration of
dopaminergic neurons in the substantia nigra, it has recently
been suggested that dopaminergic neuron death is preceded
by pathological changes in more caudal CNS regions [17]. It
has been proposed that such alterations are accompanied by
α-syn aggregations in the spinal cord [17, 23]. These ﬁndings
raisenewquestionsaboutthestartingpointofPDpathology.
We are analyzing transgenic mouse models overexpress-
ing hm2 α-syn alone (BAsyn) or in combination with a
deletion of the exon3 of the parkin gene (BAsyn/PaKO). As
these mice do not exhibit gross pathological impairments in
the mesencephalon we investigated in this study the cervical
part of the spinal cord according to the staging scheme of
Braak and coworkers [17, 23].
We ﬁrst demonstrated for both mouse lines the expres-
sion of hm2 α-syn in the spinal cord almost exclusively in
astrocytes. For neurons, microglia, and oligodendrocytes no
α-syn expression could be detected.
Following a proteinase K pretreatment α-syn aggrega-
tions were visible in all analyzed double-mutant animals and
in two out of four analyzed monomutants. These ﬁndings
could only be observed in 8m- but not in 3m-old animals.
This is in agreement with previous studies of mouse models
[24, 25] and humans [26]w h e r eα-syn aggregations only
occurred in the spinal cord but not in the substantia nigra.
These results hint towards an early involvement of the spinal
cord in the origination of PD.
In addition, inﬂammatory processes were increased in
the transgenic mice relative to LM. Transgenic mice exhibit
higher numbers of GFAP-positive astrocytes and activated
microglia. Furthermore, the lysosomal cystein proteases
CATS and CATX are more abundantly expressed in the6 Parkinson’s Disease
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Figure 3: Mitochondrial ultrastructure in the spinal cord of 8m-old BAsyn/PaKO. Exemplary ultrastructuralfeatures of neurons, astrocytes,
and oligodendrocytes are shown for LM ((a)–(c)) and BAsyn/PaKO ((d)–(f)). Higher magniﬁcations show examples of healthy or damaged
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Figure 4: Footprint analyzes of BAsyn and BAsyn/PaKO. Footprints (a) and stride length ((b), (c)). The stride lengths of 8–10 mice per
group were determined, error bars = SD, U-test, ∗P<. 05.
cervical spinal cord of BAsyn and BAsyn/PaKO compared
to LM. These inﬂammatory processes are accompanied by
ongoing cell death, as shown by FluoroJade and Gallyas
staining. Analyzes of adjacent slices could identify most cells
positive for cell death staining as astrocytes.
Interestingly, these changes only occur during aging, as
3m-old mice are not aﬀected. This reinforces the hypothesis
that early PD pathology builds up during aging [27]. All
four BAsyn/PaKO mice analyzed displayed the pathological
impairments described above whereas the appearance of
inﬂammation and cell death occurred only in two out of
four BAsyn animals. This suggests that the eﬀect of the
overexpression of α-syn is enhanced by the deletion of the
parkin gene. This may possibly be explained by the fact thatParkinson’s Disease 7
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Figure 5: Elevated plus test performance of 8m-old BAsyn and BAsyn/PaKO. Walked distance ((a), (e)),duration of stops ((b), (f)),number
of stops ((c), (g)),and time spent in closed arms ((d), (h)) are shown, n = 6–9, error bars = SD, U-test, ∗P<. 05, ∗∗P<. 01.
parkin is involved in the degradation of alpha-synuclein [5].
However, the combination of both was not seen to enhance
c e l ld e a t hi na s t r o c y t e si ns i m i l a rm o d e ls y s t e m s[ 28].
In addition, the double-mutants exhibit high mitochon-
drial damage in astrocytes and oligodendrocytes of the
cervical spinal cord, indicating a severe glial reaction that is
associated with the appearance of astrocytic cell death. The
highest mitochondrial damage occurs in oligodendrocytes,
even though they do not express the transgene. Inclusions
of α-syn in oligodendrocytes from transgenic mouse models
of MSA which overexpress alpha-synuclein have been shown
to participate in neurodegeneration [14, 15]. Interestingly,
our data implicate that the expression of the transgene in
oligodendrocytes is not a necessary requirement for the
presence of damaged mitochondria in the same cell type.
In contrast, only minor ultrastructural disturbances were
detected in motor neurons, which also do not express the
transgene. The damage in neurons and, more pronounced,
in oligodendrocytes might be triggered by neighbouring
impaired astrocytes. Oligodendrocytes may be more prone
to mitochondrial damage than neurons which are already
visible in a higher number of damaged mitochondria in
LM (Figure 3(g)). The transgenic α-syn might start a patho-
logical cascade in astrocytes. Under pathological conditions
astrocytes can become reactive glia, releasing cytokines,
and reactive oxidative molecules. These cells then fail to
provide normal support to neurons [10, 29], thereby causing
mitochondrial damage in these cells. Oligodendrocytes do
not seem to play a role in promoting inﬂammation although,
like neurons, they are damaged by inﬂammatory processes.
These data implicate that the α-syn expression mimics
physiological eﬀects which may be relevant to PD or other
diseases related to alpha-synuclein expression.
All pathological ﬁndings—gliosis, inﬂammation, cell
death, and mitochondrial damage—occurred in the AH,
ZI, LF, and in the AF of the cervical spinal cord of the
transgenic mice. This may resemble mouse models for α-
synucleinopathies, where astrogliosis emerged in the spinal
cord [30, 31]. No changes could be observed in the posterior
funiculus (PF) or the posterior horn (PH). The detected
alterations are in accordance with the appearance of α-
syn aggregations. Consisting mainly of motor neurons, AH,
and AF are the most aﬀected regions leading to motor
impairments. Though motor neurons are not structurally
aﬀected, they are surrounded by altered glial cells which may
lead to changes in neuronal function and, therefore, initiate
PD symptoms. This hypothesis is strengthened by the data
of the footprint analyses. At the age of 8m both transgenic
lines display motor impairments like gait disturbances very
similar to the symptoms in PD patients [32]. Furthermore,
the Elevated Plus Test was used to measure the tendency of
mice to explore a new environment. The test is based on the
natural aversion of mice for open and elevated areas, as well
as on their natural spontaneous exploratory behavior [33].8 Parkinson’s Disease
We found severe deﬁcits in the performance of both mouse
lines compared to the LM. The unwillingness of the mice to
explore a new environment, measured by this test, could be
due to their gait disturbances.
Our mouse models express the α-syn under the control
of the BA promoter, leading to the expression of mutated α-
syn in astrocytes. Similarly, the parkin gene is knocked out
in every cell. Therefore, this model reﬂects the situation in
humans,ashumansexpressparkinandα-syninalmostevery
tissue. In spite of this general expression pattern, we found
the described pathology exclusively in the mouse spinal cord,
resembling the situation in early PD patients.
5. Conclusion
We demonstrated that the spinal cord of α-syn transgenic
mice is more severely aﬀected than higher brain regions.
The results support the hypothesis that α-syn overexpression
induces astrocyte-derived toxicity, leading to a pathology
of the spinal cord that also involves oligodendrocytes and
eventuallyneurons.Thismayleadtoimpairedmotorcoordi-
nation.Thenatureofthegenesinvolvedandthepathological
changes indicate a resemblance of the mouse models to
MSA or PD. Therefore, it is tempting to speculate that
pathological changes in nonneuronal cells may contribute to
α-synucleinopathies.
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